Basilea Pharmaceutica AG (LON:0QNA)
London
· Delayed Price · Currency is GBP · Price in CHF 45.73
+1.05 (2.35%)
Feb 21, 2025, 4:19 PM BST
Basilea Pharmaceutica AG Income Statement
Financials in millions CHF. Fiscal year is January - December.
Millions CHF. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2015 |
| Operating Revenue | 194.87 | 150.28 | 122.32 | 131.56 | 112.42 | Upgrade
|
| Other Revenue | 13.68 | 7.36 | 25.45 | 16.56 | 15.21 | Upgrade
|
| Revenue | 208.54 | 157.63 | 147.77 | 148.12 | 127.63 | Upgrade
|
| Revenue Growth (YoY) | 32.30% | 6.68% | -0.24% | 16.06% | -5.02% | Upgrade
|
| Cost of Revenue | 115.82 | 104.65 | 98.41 | 117.23 | 121.46 | Upgrade
|
| Gross Profit | 92.72 | 52.99 | 49.36 | 30.89 | 6.17 | Upgrade
|
| Selling, General & Admin | 31.02 | 31.08 | 28.55 | 27.89 | 27.58 | Upgrade
|
| Operating Expenses | 31.02 | 31.08 | 28.55 | 27.89 | 27.58 | Upgrade
|
| Operating Income | 61.7 | 21.91 | 20.81 | 3.01 | -21.41 | Upgrade
|
| Interest Expense | -4.34 | -11.2 | -9.85 | -8.15 | -7.59 | Upgrade
|
| Interest & Investment Income | 1.42 | 1.69 | 0.33 | 0.07 | 0.1 | Upgrade
|
| Other Non Operating Income (Expenses) | 1.49 | -1.94 | 0.81 | -1.24 | -0.49 | Upgrade
|
| EBT Excluding Unusual Items | 60.26 | 10.46 | 12.1 | -6.31 | -29.39 | Upgrade
|
| Gain (Loss) on Sale of Assets | - | - | - | 0.02 | 15.04 | Upgrade
|
| Other Unusual Items | - | - | - | -0.5 | -0.31 | Upgrade
|
| Pretax Income | 60.26 | 10.46 | 12.1 | -6.79 | -14.67 | Upgrade
|
| Income Tax Expense | -17.33 | 0.01 | -0.05 | 0.04 | 0.06 | Upgrade
|
| Net Income | 77.59 | 10.45 | 12.15 | -6.83 | -14.72 | Upgrade
|
| Net Income to Common | 77.59 | 10.45 | 12.15 | -6.83 | -14.72 | Upgrade
|
| Net Income Growth | 642.45% | -13.96% | - | - | - | Upgrade
|
| Shares Outstanding (Basic) | 12 | 12 | 12 | 12 | 10 | Upgrade
|
| Shares Outstanding (Diluted) | 14 | 12 | 12 | 12 | 10 | Upgrade
|
| Shares Change (YoY) | 14.10% | 1.67% | 2.24% | 13.62% | -4.41% | Upgrade
|
| EPS (Basic) | 6.42 | 0.87 | 1.02 | -0.58 | -1.43 | Upgrade
|
| EPS (Diluted) | 5.82 | 0.86 | 1.02 | -0.58 | -1.43 | Upgrade
|
| EPS Growth | 577.28% | -15.69% | - | - | - | Upgrade
|
| Free Cash Flow | 72.65 | 13.43 | 3.92 | -32.6 | -55.96 | Upgrade
|
| Free Cash Flow Per Share | 5.24 | 1.11 | 0.33 | -2.79 | -5.44 | Upgrade
|
| Gross Margin | 44.46% | 33.61% | 33.40% | 20.86% | 4.83% | Upgrade
|
| Operating Margin | 29.59% | 13.90% | 14.09% | 2.03% | -16.78% | Upgrade
|
| Profit Margin | 37.21% | 6.63% | 8.22% | -4.61% | -11.53% | Upgrade
|
| Free Cash Flow Margin | 34.84% | 8.52% | 2.65% | -22.01% | -43.84% | Upgrade
|
| EBITDA | 63.13 | 23.19 | 21.71 | 3.56 | -20.32 | Upgrade
|
| EBITDA Margin | 30.27% | 14.71% | 14.69% | 2.40% | -15.92% | Upgrade
|
| D&A For EBITDA | 1.43 | 1.28 | 0.9 | 0.55 | 1.09 | Upgrade
|
| EBIT | 61.7 | 21.91 | 20.81 | 3.01 | -21.41 | Upgrade
|
| EBIT Margin | 29.59% | 13.90% | 14.09% | 2.03% | -16.78% | Upgrade
|
| Effective Tax Rate | - | 0.10% | - | - | - | Upgrade
|
| Revenue as Reported | 208.54 | 157.63 | 147.77 | 148.12 | 127.63 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.